1
Total investments
0
Early stage
0
Mid stage
1
Late stage
8y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Oct 2018
Peptinov is a biotechonology company based in Cochin Hospital (Paris, France) and founded by Prof. Jean-François Zagury to develop innovative peptide-based immunotherapies to treat chronic inflammatory diseases.
Peptinov’s strategy is to induce the production of antibodies targeting self-proteins directly by the organism of the patient, through immunizations against carefully selected, highly immunogenic peptide sequences.
Peptinov’s high potential R&D platform uses the tools of bioinformatics and molecular modelling to design these peptide sequences. This platform is potentially applicable to any crystallized protein and can quickly generate peptide candidates.
Peptinov’s value proposition is built on its unique capability to develop anti-self proteins products in the current pharmaceutical markets.
Peptinovs most advanced product targets IL-6, a central pro-inflammatory cytokine involved in the pathogenesis of several diseases. Peptinovs anti-IL-6 immunotherapy is now in phase 1 clinical development.
Video of Peptinovs approach: https://youtu.be/8j0GvgqPjxQ
Experience · 1 entries
All (1)
Investments (1)
2018
Investor
Oct 2018
Peptinov is a biotechonology company based in Cochin Hospital (Paris, France) and founded by Prof. Jean-François Zagury to develop innovative peptide-based immunotherapies to treat chronic inflammatory diseases.
Peptinov’s strategy is to induce the production of antibodies targeting self-proteins directly by the organism of the patient, through immunizations against carefully selected, highly immunogenic peptide sequences.
Peptinov’s high potential R&D platform uses the tools of bioinformatics and molecular modelling to design these peptide sequences. This platform is potentially applicable to any crystallized protein and can quickly generate peptide candidates.
Peptinov’s value proposition is built on its unique capability to develop anti-self proteins products in the current pharmaceutical markets.
Peptinovs most advanced product targets IL-6, a central pro-inflammatory cytokine involved in the pathogenesis of several diseases. Peptinovs anti-IL-6 immunotherapy is now in phase 1 clinical development.
Video of Peptinovs approach: https://youtu.be/8j0GvgqPjxQ